Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
Lilly's Jaypirca significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Lilly's Jaypirca met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica
U.S. FDA approves expanded indication for Lilly's Jaypirca , the first and only non-covalent BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Lilly to present data from two positive Phase 3 studies of Jaypirca in chronic lymphocytic leukemia at the 2025 American Society of Hematology Annual Meeting
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's 'Changing the Thread Collection'
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
Standard Uranium Retains 100% Unencumbered Ownership of the Sun Dog Project Through Conclusion of Property Option Agreement
RZOLV Technologies Appoints Mary Ellen Thorburn to the Board of Directors; Announces the Retirement of Darryl Yea
